EXEL vs. KYMR: Exelixis vs. Kymera Therapeutics Stock Comparison

Company Profile

Exelixis (EXEL) and Kymera Therapeutics (KYMR) are both classified in the Biotechnology sub-industry within the broader Biotechnology industry, placing them in the closest GICS peer bucket.

Exelixis (EXEL) has more than two decades of public-market history since April 17, 2000, whereas Kymera Therapeutics (KYMR) listed on August 21, 2020 and has a much shorter record to draw on.

Price Performance

Cumulative Growth

Trailing Returns

Calendar-Year Returns

Performance Metrics

Risk Profile

Drawdown History

Return Distribution

Risk Metrics

Kymera Therapeutics (KYMR) has an aggressive beta of 2.00, indicating higher sensitivity to broad-market moves, while Exelixis (EXEL) is defensive at 0.41 and tends to be less market-sensitive — they sit on opposite ends of the beta spectrum.

Risk-Adjusted Performance

Risk-Return Positioning

Risk-Adjusted Metrics

Profitability

Kymera Therapeutics (KYMR) reports a negative ROE of -27.29%; negative ROE can reflect losses or negative shareholders’ equity, so it is harder to read as capital efficiency. Meanwhile Exelixis (EXEL) reports 44.32%, ranking against industry peers normally.

Exelixis (EXEL) at 35.45% converts revenue to bottom-line profit above its industry’s benchmark range, while Kymera Therapeutics (KYMR) at 0.00% keeps roughly the typical share for its industry.

Kymera Therapeutics (KYMR) reports a negative operating margin of -396.04%, usually indicating that operating costs exceeded revenue at the operating-income line. Meanwhile Exelixis (EXEL) reports 40.75%, ranking against industry peers normally.

Profitability Metrics

Growth

Exelixis (EXEL) at 6.98% is around its peer norm for revenue growth, while Kymera Therapeutics (KYMR) at -16.70% drops into the bottom quartile, signaling weaker demand or pricing momentum.

Only one side can be read here: Exelixis (EXEL) reports EPS growth of 57.95%, ranked against its industry; Kymera Therapeutics (KYMR) has no EPS growth figure this period.

Growth Metrics

Financial Strength

Both Exelixis (EXEL) at 3.21 and Kymera Therapeutics (KYMR) at 11.13 carry current ratio within their industries’ typical mid-ranges, suggesting balanced short-term liquidity relative to peers.

Both Exelixis (EXEL) at 0.09 and Kymera Therapeutics (KYMR) at 0.05 fund their balance sheets with roughly industry-typical debt-to-equity mixes.

Financial Strength Metrics

Dividends

Neither Exelixis (EXEL) nor Kymera Therapeutics (KYMR) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

Neither Exelixis (EXEL) nor Kymera Therapeutics (KYMR) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

Dividend Metrics

Valuation

An earnings multiple is available for just one side: Exelixis (EXEL) trades at 20.83 times trailing earnings, ranked against its peers, while Kymera Therapeutics (KYMR) has no P/E ratio this period.

Exelixis (EXEL) at 6.80 prices around its industry’s typical P/S ratio, while Kymera Therapeutics (KYMR) at 110.00 clears its benchmark range — KYMR looks notably rich on sales.

Both Exelixis (EXEL) at 9.28 and Kymera Therapeutics (KYMR) at 6.96 carry a premium to book value versus peers, sitting in the upper P/B ratio quartile of their industries.

Valuation Metrics